Aclaris Therapeutics Files 8-K
Ticker: ACRS · Form: 8-K · Filed: Jun 30, 2025 · CIK: 1557746
| Field | Detail |
|---|---|
| Company | Aclaris Therapeutics, INC. (ACRS) |
| Form Type | 8-K |
| Filed Date | Jun 30, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k
Related Tickers: ACRS
TL;DR
ACRS filed a routine 8-K on 6/30/25, no major news.
AI Summary
Aclaris Therapeutics, Inc. filed an 8-K on June 30, 2025, to report information under Regulation FD and to file financial statements and exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements for this form.
Why It Matters
This 8-K filing serves as a routine update for Aclaris Therapeutics, Inc., indicating compliance with SEC reporting requirements and the submission of necessary financial documents.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for reporting purposes and does not disclose any new material events or financial information that would inherently increase risk.
Key Players & Entities
- Aclaris Therapeutics, Inc. (company) — Registrant
- June 30, 2025 (date) — Date of earliest event reported
FAQ
What is the purpose of this 8-K filing for Aclaris Therapeutics, Inc.?
The 8-K filing is to report information under Regulation FD Disclosure and to file Financial Statements and Exhibits.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported is June 30, 2025.
What is the principal executive office address for Aclaris Therapeutics, Inc.?
The address of the principal executive offices is 701 Lee Road, Suite 103, Wayne, PA 19087.
What is the telephone number for Aclaris Therapeutics, Inc.?
The registrant's telephone number is (484) 324-7933.
What is the state of incorporation for Aclaris Therapeutics, Inc.?
Aclaris Therapeutics, Inc. is incorporated in Delaware.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 30, 2025 regarding Aclaris Therapeutics, Inc. (ACRS).